BlackRock’s GALENA BIOPHARMA INC COM RXII Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2016
Q4 | – | Sell |
-12,812
| Closed | -$4K | – | 3892 |
|
|
2016
Q3 | $4K | Hold |
12,812
| – | – | ﹤0.01% | 3539 |
|
|
2016
Q2 | $6K | Buy |
12,812
+2,581
| +25% | +$1.21K | ﹤0.01% | 3505 |
|
|
2016
Q1 | $14K | Buy |
10,231
+6,703
| +190% | +$9.17K | ﹤0.01% | 3030 |
|
|
2015
Q4 | $5K | Hold |
3,528
| – | – | ﹤0.01% | 3191 |
|
|
2015
Q3 | $6K | Hold |
3,528
| – | – | ﹤0.01% | 2986 |
|
|
2015
Q2 | $6K | Sell |
3,528
-1,143
| -24% | -$1.94K | ﹤0.01% | 3115 |
|
|
2015
Q1 | $6K | Buy |
4,671
+1,112
| +31% | +$1.43K | ﹤0.01% | 3011 |
|
|
2014
Q4 | $5K | Hold |
3,559
| – | – | ﹤0.01% | 3097 |
|
|
2014
Q3 | $7K | Buy |
3,559
+782
| +28% | +$1.54K | ﹤0.01% | 2988 |
|
|
2014
Q2 | $8K | Sell |
2,777
-613
| -18% | -$1.77K | ﹤0.01% | 2978 |
|
|
2014
Q1 | $8K | Buy |
3,390
+636
| +23% | +$1.5K | ﹤0.01% | 2906 |
|
|
2013
Q4 | $14K | Sell |
2,754
-376
| -12% | -$1.91K | ﹤0.01% | 2553 |
|
|
2013
Q3 | $7K | Buy |
3,130
+724
| +30% | +$1.62K | ﹤0.01% | 2909 |
|
|
2013
Q2 | $5K | Buy |
+2,406
| New | +$5K | ﹤0.01% | 3070 |
|
BlackRock's RXII Position: Q4 2016 in Review
BlackRock sold out of GALENA BIOPHARMA INC COM (RXII) in Q4 2016, closing a stake of 12,812 shares — an estimated $4K sold.
BlackRock first reported a position in RXII in Q2 2013 and held it in 14 quarters. The position peaked at $14K in Q1 2016. 0 funds tracked by Wall St. Rank hold RXII as of Q4 2016.
- BlackRock reported no remaining GALENA BIOPHARMA INC COM position as of Q4 2016 after selling out during the quarter.
- BlackRock sold 12,812 GALENA BIOPHARMA INC COM shares in Q4 2016, an estimated $4K.
- BlackRock first reported a position in GALENA BIOPHARMA INC COM in Q2 2013 and held it in 14 quarters.
- BlackRock's GALENA BIOPHARMA INC COM position peaked at $14K in Q1 2016.
- 0 funds tracked by Wall St. Rank held GALENA BIOPHARMA INC COM as of Q4 2016.
Based on BlackRock's 13F filing for Q4 2016, filed 10 Feb 2017.